MedTrace Logo

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2025-12-17

No results posted yet for this study

Summary

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy

Conditions

  • Epilepsy, Tonic-Clonic
  • Focal Seizure
  • Primary Generalized Seizure

Interventions

DRUG

vormatrogine

Once daily oral

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Praxis Precision Medicines

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-27
Primary Completion
2028-05-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07287163 on ClinicalTrials.gov